Substance Abuse clinical trials at UCLA
10 in progress, 7 open to eligible people
AnalgeSiC and appEtite-stimulating Effects of caNnabigerol and THC (ASCENT)
open to eligible people ages 21-55
This study will assess the analgesic, appetite-stimulating, and subjective effects of cannabigerol (CBG) alone and in combination with THC.
Los Angeles, California
Analgesic and Subjective Effects of Terpenes
open to eligible people ages 21-55
The purpose of this research is to assess the analgesic and subjective effects of terpenes administered alone and in combination of THC.
Los Angeles, California
Cannabis Effects as a Function of Sex (CanSex)
open to eligible people ages 21-55
The purpose of this research is to assess the impact of cannabis on the analgesic and abuse-related effects between men and women
Los Angeles, California
ASK-PrEP (Assistance Services Knowledge-PrEP)
open to eligible males ages 18 years and up
ASK-PrEP is a two-arm randomized controlled trial (RCT), with a Stepped Care approach, among HIV-negative trans women and men who have sex with men with a substance use disorder (SUD). Participants will be randomized (3:1) to the ASK-PrEP Stepped Care arm or Standard of Care (SOC). Participants in the ASK-PrEP Stepped Care arm will receive 5 PrEP navigation sessions, with weekly text-messaging support, delivered over 3 months, at which point they will be assessed for intervention response. Responders will be maintained for an additional 3 months in ASK-PrEP to receive an additional 5 PrEP navigation session with weekly text-messaging support, while non-responders will receive added attention to their SUD via contingency management (CM). Non-responders will be re-randomized (1:1) to either a) receive ASK-PrEP + CM, or b) shift the primary focus to their SUD (CM alone) for an additional 3 months.
Los Angeles, California
Smoked THC and CBD in Men and Women
open to eligible people ages 21-55
The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of inhaled cannabis with varying amounts of delta-9-tetrahydrocannabinol (THC), and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.
Los Angeles, California
Expression of Stress Markers During Meth Treatment (EXPRESS+)
open to eligible males ages 18-45
This is a non-randomized behavioral trial that aims to investigate whether changes in inflammatory and type I IFN expression coincide with changes in methamphetamine use and viral load over the course of 12 weeks in HIV-positive people assigned male at birth with and without methamphetamine use disorder.
Los Angeles, California
Patient Decision Aid for Opioid Use Disorder
open to eligible people ages 18 years and up
The aim of the study is to test the effectiveness of the Patient Decision Aid for Opioid Use Disorder (PtDA-MAT) by conducting a stepped-wedge cluster-randomized trial in CA H&SS (stratified by rural vs. non-rural areas) for adults with OUD. Patient outcomes will be tracked by (1) personal assessments (baseline, 3 months, and 6 months): drug use, overdose, healthcare utilization, and (2) clinical and administrative records (over approximately 24 months): drug treatment status and retention, physical and mental health diagnoses, arrest, incarceration, controlled substance use, and mortality. Multilevel models will be applied to test the intervention effects, controlling for possible temporal trends.
Los Angeles, California
Age-dependent Effects of Smoked and Oral Delta-9-THC
Sorry, not yet accepting patients
This study will assess the age-dependent effects of smoked and oral THC on abuse liability, intoxication, analgesia and impairment as a function of age.
Oral THC and CBD in Men and Women
Sorry, not yet accepting patients
The purpose of this study is to determine the pharmacokinetics and pharmacodynamics of oral delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and to evaluate detection of recently smoked THC in oral fluid.
Los Angeles, California
uTECH: Machine Learning for HIV Prevention Among Substance Using GBMSM
Sorry, in progress, not accepting new patients
This project seeks to develop and test the acceptability, appropriateness and feasibility of uTECH, a novel social media "big data" machine learning intervention for HIV-negative substance-using sexual and gender minority people who have sex with men that aims to reduce HIV transmission risk by integrating biomedical and behavioral risk reduction strategies, including pre-exposure prophylaxis (PrEP) for HIV prevention and medication assisted treatment (MAT) for substance use harm reduction
Los Angeles, California
Our lead scientists for Substance Abuse research studies include Larissa Mooney, M.D. Ziva D Cooper, PhD Michael J Li, PhD.
Last updated: